ClinicalTrials.govpublic full text
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
hereditary angioedema, autosomal dominant disease, hereditary angioedema attack, monoclonal antibody, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 834998
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.